A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.

Trial Profile

A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Encenicline (Primary) ; Moxifloxacin
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 16 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
    • 16 Jul 2013 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2012 Planned end date changed from 1 May 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top